← Russell 3000 cross-section

DOCS Doximity, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Technology

Scale

Market cap
$4.4bn
Revenue TTM
$656m
Net income TTM
$167m
Free cash flow
Composite score
64.7
Sector rank
#1163

Valuation

P / E
26.4
EV / EBITDA
19.7
EV / sales
6.3
FCF yield
Earnings yield vs 10-yr
-0.94pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
25.5%
EBITDA margin
32.0%
ROE
18.2%
ROIC
30.2%
Revenue growth
11.2%

Insider activity, last 90 days

Net open-market
$-0.48m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our revenue-generating customers, primarily pharmaceutical manufacturers and health systems, have access to a suite of commercial solutions that benefit from broad physician usage. Our business model has delivered high revenue growth at scale with profitability. For the three months ended June 30, 2026 and 2025, we recognized revenue of $156.6 million and $145.9 million, respectively, representing a year-over-year growth rate of 7%. For the three months ended June 30, 2026 and 2025, our net income was $24.3 million and $53.3 million and our adjusted EBITDA was $74.8 million and $79.8 million, respectively. …Doximity, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →